A double-blind randomized trial of two dose regimens of misoprostol for cervical ripening and labor induction.

OBJECTIVES: The objective of this study was to compare the efficacy and safety of two dosing regimens of misoprostol for cervical ripening and labor induction. METHODS: Patients who fulfilled the study criteria were randomized to received misoprostol 25 microg or 50 microg intravaginally every 3 h for a total of eight doses for cervical ripening or until labor was established. Endpoints for successful cervical ripening was achievement of Bishop score of nine or greater, and for labor induction reaching the active phase of labor in the first 24 h. The rates of success, duration of first and second stages of labor, type of delivery, significant side effects, and neonatal outcome were measured and compared between the two study groups. Two hundred and fifty-one patients were randomized in two groups--126 received 50 microg and 125 received 25 microg misoprostol. Demographics of the two study groups were similar. RESULTS: Patients in the 50 microg group had a shorter first stage (848 min vs. 1,122 min, P < 0.007), shorter induction-to-vaginal delivery interval (933 min vs. 1,194 min, P < 0.013), decreased incidence of oxytocin augmentation (53.9% vs. 68%, P < 0.015), and decreased total units of oxytocin (2,763 mU vs. 5,236 mU, P < 0.023), but there was a higher hyperstimulation rate (19% vs. 7.2%, P < 0.005). CONCLUSIONS: Successful induction rate, delivery types, and fetal outcome were similar in both groups. Although the rate of vaginal delivery and neonatal outcome were similar in both groups, the 50 microg regimen had shorter first and second stages of labor, and a higher hyperstimulation rate that was easily manageable, allowing for flexibility in using the higher dose in low-risk pregnancies.

Pulmonary artery sarcoma in a pregnant woman: report of a case.

BACKGROUND: We report the case of a 23-year-old pregnant woman with hemoptysis, cor pulmonale, and pulmonary artery sarcoma. The physiologic changes of pregnancy may have unmasked the pulmonary lesion. CASE: A 23-year-old woman presented at 28 weeks' gestation with acute onset of hemoptysis and dyspnea. A hilar mass was noted and a pulmonary embolus was diagnosed. Biopsy of the hilar mass was nondiagnostic. Emergency cesarean delivery was performed because of rapid clinical deterioration and an acute loss of fetal heart tones. Both mother and infant died. Autopsy of the mother demonstrated a large pulmonary artery sarcoma with metastases to both lungs and terminal bacterial bronchopneumonia. CONCLUSION: Hemodynamic changes of pregnancy may have unmasked the pulmonary lesion in this case. Pulmonary artery sarcoma is an extremely rare tumor.

Alzheimer's disease. Beta-amyloid precursor protein expression in the nucleus basalis of Meynert.

The nucleus basalis of Meynert (nbM) was examined using immunocytochemistry for beta-amyloid precursor protein (beta APP) expression in Alzheimer's disease (AD). In mild AD cases, light labeling of the cell body and proximal processes was observed, and small intracellular structures were labeled rarely. In the more severe cases, intense cytoplasmic beta APP labeling was seen, often along with small beta APP-positive structures. Double-labeling experiments demonstrated that in the more severe cases these small structures were also decorated by a neurofibrillary tangle (NFT) antiserum. Other neurons in the severe cases showed incorporation of beta APP into large inclusions, which were also labeled with the NFT antiserum. However, some large inclusions in the severe cases were labeled by the NFT antiserum but contained no beta APP. Extraneuronal NFTs did not show beta APP labeling and did not react with an antibody to the beta-amyloid peptide. These results suggest that increased expression of beta APP coincides with intracellular NFT formation in the nbM, but that the formation of extraneuronal NFTs results in a loss of beta APP immunoreactivity.

Alzheimer's disease: beta-amyloid precursor protein expression in plaques varies among cytoarchitectonic areas of the medial temporal lobe.

The anatomic distributions of beta-amyloid peptide (beta AP) and beta-amyloid precursor protein (beta APP) in the medial temporal lobe were examined with immunocytochemistry in Alzheimer's disease. beta AP-containing plaques were found most frequently in the cortical and basal regions of the amygdala, and in the hippocampal CA1, subiculum, and dentate molecular layer. beta APP expression in plaques was found in a similar distribution, with some, but not all beta AP plaques also showing beta APP. In the cortical and basal amygdala, some cases showed beta APP in the centers of plaques, whereas in the hippocampus, all cases displayed beta APP mainly in plaque neurites. The lateral regions of the amygdala contained mainly diffuse beta AP plaques which had little beta APP. These findings suggest that although beta APP expression and beta AP deposition generally colocalize, processing of beta APP may vary among closely interconnected anatomic regions.

An osmotic gradient in ischemic brain edema.

We studied how the osmotic pressure gradient between blood and the brain is related to the development of ischemic brain edema. Focal cerebral ischemia was produced by left MCA occlusion in rats. Brain osmolality was determined with a vapor pressure osmometer, water content of the brain tissue was measured by wet and dry weight, and the tissue sodium and potassium contents were assayed by flame photometry. Permeability of BBB was tested by EB. These measurements were made from the cortical core of MCA territory at various intervals from 1 hr to 14 days after occlusion. Brain osmolality increased from 311 +/- 2 mOsm/kg (M +/- SE) to 329 +/- 2 mOsm/kg (n = 7, p less than 0.01) by 6 hrs after occlusion. Serum osmolality did not significantly change. The osmotic gradient between blood and the brain was about 26 mOsm/kg. Brain osmolality then decreased to 310 +/- 2 mOsm/kg by 12 hr after occlusion and remained about the same level for up to 14 days. Water content progressively increased within 1 day, then gradually decreased by 14 days. Sodium plus potassium content of the brain tissue did not increase and EB extravasation was not seen within 6 hr of occlusion. These findings indicate that an osmotic pressure gradient contributes to the formation of edema only during the early stage of cerebral ischemia. Brain osmolality is not related to tissue electrolyte change and BBB disruption to protein.

Ischemic brain edema and the osmotic gradient between blood and brain.

The relationship of the osmotic pressure gradient between blood and brain, and the development of ischemic brain edema was studied. Focal cerebral ischemia was produced by left middle cerebral artery occlusion in rats. Brain osmolality was determined with a vapor pressure osmometer, brain water content by wet-dry weight, and tissue sodium and potassium contents by flame photometry. Permeability of the BBB was tested by Evans blue. Measurements were made from the ischemic cortex within 14 days of occlusion. Brain osmolality increased from 311 +/- 2 to 329 +/- 2 mOsm/kg by 6 h after occlusion. Serum osmolality did not change significantly. The osmotic gradient between blood and brain peaked at approximately 26 mOsm/kg. Brain osmolality then decreased to 310 +/- 2 mOsm/kg by 12 h after occlusion and remained at about that same level. Water content increased progressively within 1 day of occlusion, then gradually decreased by 14 days. Brain tissue sodium plus potassium content did not increase within 6 h of occlusion, and Evans blue extravasation was not seen within that time. These findings indicate that an osmotic pressure gradient contributes to the formation of edema only during the early stage of cerebral ischemia. Furthermore, the increase in brain osmolality is not related to tissue electrolyte change or BBB disruption to protein.